Literature DB >> 19734373

Is a thorough QTc study necessary? The role of modeling and simulation in evaluating the QTc prolongation potential of drugs.

Shashank Rohatagi1, Timothy J Carrothers, Jon Kuwabara-Wagg, Tatiana Khariton.   

Abstract

Concentration-QT (C-QT) modeling has been conducted for multiple compounds at various stages of development in different therapeutic areas. Data from available single and multiple ascending-dose (SAD/MAD) studies were pooled to construct population C-QT models, with post hoc predictions of concentration from a pharmacokinetic model. All SAD and MAD studies employed a customized robust QTc assessment with time-matched triplicate electrocardiograms and centralized manual QTc reading. Sources of variability were characterized, and the relationship between covariates and model parameters was explored, with a particular emphasis on correction for heart rate and diurnal variation. The results of population prediction of QTc prolongation were compared to available thorough QTc (TQT) study results, and the C-QT model was evaluated to determine whether it could establish the QTc prolongation relationship without the TQT results. Negative TQT study results confirmed negative simulation results from phase I/II C-QT models. Simulations were undertaken to characterize the ability of pooled C-QT modeling to obviate the need for a TQT. C-QT modeling should be implemented as a standard part of modeling and simulation at different phases of drug development and used in conjunction with other data that influence the need and/or the timing of a TQT study.

Entities:  

Mesh:

Year:  2009        PMID: 19734373     DOI: 10.1177/0091270009341184

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  17 in total

Review 1.  The IQ-CSRC prospective clinical Phase 1 study: "Can early QT assessment using exposure response analysis replace the thorough QT study?".

Authors:  Borje Darpo; Nenad Sarapa; Christine Garnett; Charles Benson; Corina Dota; Georg Ferber; Venkateswar Jarugula; Lars Johannesen; James Keirns; Kevin Krudys; Catherine Ortemann-Renon; Steve Riley; Danise Rogers-Subramaniam; Norman Stockbridge
Journal:  Ann Noninvasive Electrocardiol       Date:  2013-12-30       Impact factor: 1.468

2.  Replacing the thorough QT study: reflections of a baby in the bath water.

Authors:  Robert B Kleiman; Rashmi R Shah; Joel Morganroth
Journal:  Br J Clin Pharmacol       Date:  2014-08       Impact factor: 4.335

3.  Detection of QTc effects in small studies--implications for replacing the thorough QT study.

Authors:  Georg Ferber; Meijian Zhou; Borje Darpo
Journal:  Ann Noninvasive Electrocardiol       Date:  2014-11-04       Impact factor: 1.468

4.  Implications of the IQ-CSRC Prospective Study: Time to Revise ICH E14.

Authors:  Borje Darpo; Christine Garnett; James Keirns; Norman Stockbridge
Journal:  Drug Saf       Date:  2015-09       Impact factor: 5.606

5.  Comparison of Digital 12-Lead ECG and Digital 12-Lead Holter ECG Recordings in Healthy Male Subjects: Results from a Randomized, Double-Blinded, Placebo-Controlled Clinical Trial.

Authors:  Duolao Wang; Ameet Bakhai; Radivoj Arezina; Jörg Täubel
Journal:  Ann Noninvasive Electrocardiol       Date:  2016-03-28       Impact factor: 1.468

Review 6.  Early investigation of QTc liability: the role of multiple ascending dose (MAD) study.

Authors:  Rashmi R Shah; Joel Morganroth
Journal:  Drug Saf       Date:  2012-09-01       Impact factor: 5.606

7.  Cardiac risk assessment based on early Phase I data and PK-QTc analysis is concordant with the outcome of thorough QTc trials: an assessment based on eleven drug candidates.

Authors:  Puneet Gaitonde; Yeamin Huh; Borje Darpo; Georg Ferber; Günter Heimann; James Li; Kaifeng Lu; Bernard Sebastien; Kuenhi Tsai; Steve Riley
Journal:  J Pharmacokinet Pharmacodyn       Date:  2019-10-30       Impact factor: 2.745

8.  Losmapimod concentration-QT relationship in healthy volunteers: meta-analysis of data from six clinical trials.

Authors:  Shuying Yang; Misba Beerahee
Journal:  Eur J Clin Pharmacol       Date:  2013-01-17       Impact factor: 2.953

9.  Assessing QT/QTc interval prolongation with concentration-QT modeling for Phase I studies: impact of computational platforms, model structures and confidence interval calculation methods.

Authors:  Jingtao Lu; Jianguo Li; Gabriel Helmlinger; Nidal Al-Huniti
Journal:  J Pharmacokinet Pharmacodyn       Date:  2018-03-19       Impact factor: 2.745

10.  Concentration-QT analysis of the randomized, placebo- and moxifloxacin-controlled thorough QT study of umeclidinium monotherapy and umeclidinium/vilanterol combination in healthy subjects.

Authors:  Rashmi Mehta; Michelle Green; Bela Patel; Jonathan Wagg
Journal:  J Pharmacokinet Pharmacodyn       Date:  2016-01-06       Impact factor: 2.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.